Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by toinv261on Mar 12, 2014 7:37pm
384 Views
Post# 22316405

A few thoughts

A few thoughtsRVX/Zenith Management
One of the things that has been bothering me is what kind of company did I invest in? I hadn't paid attention since I put money in 5 years ago. Because of the slow progress I was beginning to think perhaps I had invested in some wild west company.

Well, I think I proved that hypothesis completely wrong. I read the bios of the board members, management team and each advisory board's members and as you all probably know it is very impressive.
  1. There is an incredible depth of scientific and pharma experience.
  2. In terms of scientiific profile some of these people have published many research papers and thus probably have high recognition and respect.
  3. A number of these people have held business development positions across various companies.
  4. The experience and reach across pharma companies is very significant.

This seems like a remarkable team of great intellectual strength and also connections in the pharma industry. It certainly reassures me of the talent, dedication and integrity of their human resources.

So I don't think the issues reside with the science, lack of integrity or lack of intellectual strength. I feel very assured.

Post hoc analysis of rvx-208 is very positive. How can this be packed in a deal and leveraged with the wider retail shareholder market (who should be recognized as important to Resverlogix).

Zenith IPO
Sanfran, I understand your POV regarding the Zenith IPO being done after the Resverlogix deal is done. I'm fine with that as long the the Resverlogix deal is done before mid April, and I, like most, am completely in the dark about the status of RVX...but hopeful.

I know I am becoming redundant regarding the Zenith IPO but I'll express my thoughts one more time.
  1. It's been 10 months since Zenith was split out from RVX.
  2. There would have been 8 to 12 months of planning this before the filing (i.e. management has had a long time to think about this).
  3. I believe that in the structuring of the spin off Zenith was provided a significant amount of funding ($3MM+) that would be one of the criteria required for a listing.
  4. I also remember that the structure of the financial data would fit the requirements for a listing.
  5. The website for Zenith was launched in September 2013.
  6. Parallel to that should have been the structuring of the information required for a listing on the TSX and NASDAQ.
  7. And parallel to that should have been a complete PR plan to leverage the IPO.

So my bottom line is that I'd like to see the IPO in April 2014 particularly given that there were no concrete plans presented in February.

I respect the fact that the company must keep confidentiality on deals they are working on but the structuring, which I favoured, that happened last spring gave every suggestion of an IPO.

Anyway, some thoughts.
Cheers
Toinv











 
Bullboard Posts